Source comparison
MOTS-c Mechanism of Action Detailed: Administration Comparison
Before selecting a MOTS-c research protocol, understanding how different administration routes and dosing schedules affect the peptide's dual cytoplasmic-nuclear mechanisms helps optimize experimental design and outcome measurement. Subcutaneous injection (0.5
This comparison does not assign a generated winner or score.
- Before selecting a MOTS-c research protocol, understanding how different administration routes and dosing schedules affect the peptide's dual cytoplasmic-nuclear mechanisms helps optimize experimental design and outcome measurement.
- Subcutaneous injection (0.5–1mg daily)
- Peak plasma concentration 1–2 hours; half-life 4–6 hours; sustained AMPK activation 18–24 hours
- Primarily cytoplasmic AMPK pathway; nuclear translocation occurs under metabolic stress conditions
- Metabolic disorder models, insulin resistance studies, short-term glucose disposal research
- Most consistent for daily metabolic effect studies; requires daily dosing for sustained AMPK activation
- Intravenous bolus (1–2mg single dose)
- Immediate peak concentration; rapid clearance within 6–8 hours; transient AMPK spike
- Acute AMPK activation without sustained nuclear effects unless combined with exercise or fasting protocol
- Acute metabolic challenge studies, exercise performance research, ischemia-reperfusion models
- Best for controlled timing of metabolic response; nuclear effects require co-administration of metabolic stressor
- Intermittent high-dose (5mg 2–3× weekly)
- Supraphysiological peak followed by clearance; mimics pulsatile endogenous MDPs
- Both cytoplasmic and nuclear pathways; higher likelihood of stress-induced nuclear translocation at peak concentration
- Aging models, mitochondrial biogenesis studies, long-term metabolic adaptation research
- Allows assessment of nuclear transcriptional effects; closer to endogenous MDP pulsatile pattern
- Oral delivery (experimental liposomal/nanoparticle formulations)
- Variable; 15–30% bioavailability depending on carrier; hepatic first-pass metabolism significant
- Primarily hepatic AMPK activation; limited systemic skeletal muscle effects compared to injection
- Hepatic insulin resistance models, NAFLD research, translational human application development
- Currently limited to experimental protocols; commercial formulations not yet validated for research-grade consistency